Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$38.62 +5.1%	$31.66	$16.50 ▼ $43.58	$3.36B	N/A	47,742 shs	12,404 shs
MRUS Merus	$56.52 +2.8%	$51.31	$33.19 ▼ $62.98	$3.91B	1	731,885 shs	646,221 shs
NRIX Nurix Therapeutics	$12.43 +2.3%	$11.32	$8.18 ▼ $29.56	$950.26M	2.15	849,321 shs	774,871 shs
RARE Ultragenyx Pharmaceutical	$27.31 +0.4%	$36.12	$26.85 ▼ $60.37	$2.58B	0.26	956,604 shs	3.04 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	+1.55%	-11.10%	+16.66%	+94.81%	+3,675,999,900.00%
MRUS Merus	-1.13%	+5.08%	+0.70%	+31.21%	-5.35%
NRIX Nurix Therapeutics	-4.26%	-0.49%	+1.84%	+23.98%	-46.43%
RARE Ultragenyx Pharmaceutical	-6.94%	-31.00%	-27.45%	-22.24%	-38.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRUS Merus	1.9313 of 5 stars	3.6	1.0	0.0	0.0	2.1	2.5	0.0
NRIX Nurix Therapeutics	2.4413 of 5 stars	4.4	1.0	0.0	0.0	3.0	0.8	0.0
RARE Ultragenyx Pharmaceutical	4.3635 of 5 stars	4.5	1.0	0.0	3.8	2.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
MRUS Merus	3.14	Buy	$84.64	49.75% Upside
NRIX Nurix Therapeutics	2.82	Moderate Buy	$29.31	135.82% Upside
RARE Ultragenyx Pharmaceutical	2.93	Moderate Buy	$83.64	206.27% Upside

Current Analyst Ratings Breakdown

Latest NRIX, RARE, AAPG, and MRUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $16.00
7/14/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
7/14/2025	RARE Ultragenyx Pharmaceutical	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$35.00 ➝ $34.00
7/14/2025	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$65.00 ➝ $55.00
7/10/2025	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $26.00
7/10/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/10/2025	NRIX Nurix Therapeutics	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00
7/10/2025	RARE Ultragenyx Pharmaceutical	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$88.00 ➝ $65.00
6/20/2025	RARE Ultragenyx Pharmaceutical	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00
5/28/2025	RARE Ultragenyx Pharmaceutical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$134.35M	25.04	N/A	N/A	$0.48 per share	80.46
MRUS Merus	$54.73M	71.48	N/A	N/A	$9.46 per share	5.97
NRIX Nurix Therapeutics	$88.38M	10.75	N/A	N/A	$5.85 per share	2.12
RARE Ultragenyx Pharmaceutical	$590.69M	4.37	N/A	N/A	$2.76 per share	9.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$55.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MRUS Merus	-$215.33M	-$4.08	N/A	N/A	N/A	-506.73%	-35.99%	-29.83%	7/30/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.61	N/A	N/A	N/A	-234.57%	-45.26%	-34.71%	N/A
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.88	N/A	N/A	N/A	-93.04%	-186.49%	-36.81%	7/30/2025 (Estimated)

Latest NRIX, RARE, AAPG, and MRUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q1 2025	MRUS Merus	-$1.17	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	RARE Ultragenyx Pharmaceutical	-$1.27	N/A	N/A	N/A	N/A	N/A
7/9/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.79	-$0.52	+$0.27	-$0.52	$16.26 million	$44,056.00 billion
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/6/2025	Q1 2025	RARE Ultragenyx Pharmaceutical	-$1.54	-$1.57	-$0.03	-$1.57	$145.98 million	$139.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	3.24	1.26	1.26
MRUS Merus	N/A	5.86	5.86
NRIX Nurix Therapeutics	N/A	6.82	6.82
RARE Ultragenyx Pharmaceutical	N/A	2.40	2.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
MRUS Merus	96.14%
NRIX Nurix Therapeutics	N/A
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
MRUS Merus	4.57%
NRIX Nurix Therapeutics	7.40%
RARE Ultragenyx Pharmaceutical	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	87.12 million	N/A	N/A
MRUS Merus	37	69.21 million	66.05 million	Optionable
NRIX Nurix Therapeutics	300	76.45 million	70.79 million	Optionable
RARE Ultragenyx Pharmaceutical	1,294	94.54 million	89.34 million	Optionable

NRIX, RARE, AAPG, and MRUS Headlines

Recent News About These Companies

William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE)

July 16 at 10:43 AM | insidermonkey.com

FY2025 EPS Estimates for RARE Cut by Cantor Fitzgerald

July 16 at 6:46 AM | marketbeat.com

William Blair Has Bearish Estimate for RARE FY2025 Earnings

July 16 at 6:46 AM | marketbeat.com

Wedbush Analysts Decrease Earnings Estimates for RARE

July 16 at 6:25 AM | marketbeat.com

Morgan Stanley Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

July 16 at 4:09 AM | americanbankingnews.com

Ultragenyx hit again, this time with a CRL in rare disease

July 15 at 10:19 PM | bioworld.comB

Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA

July 15 at 10:19 PM | msn.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading Down 5.7% on Analyst Downgrade

July 15 at 11:57 AM | marketbeat.com

Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA

July 15 at 9:31 AM | zacks.com

Q4 EPS Forecast for Ultragenyx Pharmaceutical Cut by Analyst

July 15 at 8:23 AM | marketbeat.com

Ultragenyx: The High Stakes Of Binary Events And A Short Cash Runway

July 15 at 6:55 AM | seekingalpha.com

Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A Rejection

July 14 at 10:14 AM | investors.com

Wedbush Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

July 14 at 9:32 AM | marketbeat.com

Ultragenyx receives CRL from US FDA for UX111 AAV gene therapy to treat Sanfilippo syndrome type A

July 14 at 9:27 AM | pharmabiz.comP

Ultragenyx receives complete response letter for UX111 BLA

July 14 at 9:27 AM | finance.yahoo.com

Ultragenyx hit with FDA delay for gene therapy targeting rare childhood disorder

July 14 at 9:27 AM | thepharmaletter.comT

Morgan Stanley Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $55.00

July 14 at 9:04 AM | marketbeat.com

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

July 14 at 8:14 AM | benzinga.com

Equities Analysts Set Expectations for RARE Q2 Earnings

July 14 at 2:23 AM | marketbeat.com

January 2027 Options Now Available For Ultragenyx Pharmaceutical (RARE)

July 13 at 6:22 PM | nasdaq.com

Ultragenyx (RARE) Falls 26% as New Treatment Fails to Get FDA Green Light

July 13 at 3:28 PM | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500
By Sam Quirke | June 30, 2025
View Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500
Why Qualcomm’s Latest Price Target Can't Be Ignored
By Sam Quirke | June 24, 2025
View Why Qualcomm’s Latest Price Target Can't Be Ignored
MP Materials Stock Booms on New Government Positioning
By Gabriel Osorio-Mazilli | July 14, 2025
View MP Materials Stock Booms on New Government Positioning
Top 5 Undervalued Dividend Stocks With Strong Payout Potential
By Ryan Hasson | July 7, 2025
View Top 5 Undervalued Dividend Stocks With Strong Payout Potential

NRIX, RARE, AAPG, and MRUS Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$38.62 +1.86 (+5.06%)

As of 03:59 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Merus NASDAQ:MRUS

$56.52 +1.53 (+2.78%)

Closing price 04:00 PM Eastern

Extended Trading

$54.89 -1.63 (-2.88%)

As of 05:22 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Nurix Therapeutics NASDAQ:NRIX

$12.43 +0.28 (+2.30%)

Closing price 04:00 PM Eastern

Extended Trading

$12.42 0.00 (-0.04%)

As of 05:41 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Ultragenyx Pharmaceutical NASDAQ:RARE

$27.31 +0.11 (+0.40%)

Closing price 04:00 PM Eastern

Extended Trading

$27.31 0.00 (0.00%)

As of 05:44 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time